Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

5.03
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
4.39
Today|||52-Week Range
12.50
-5.98%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$469.7M

Company Description

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
55 Collins Street
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:
(212) 880-2060

Employees

Shareholders

Mutual fund holders2.14%
Other institutional0.50%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, MD & Executive Director
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Paul SimmonsHead-Research & New Product Development
Michael SchusterHead-Pharma Partnering